Sigma-Aldrich Introduces MISSION® In VIVO QUALITY and iScale Oligos™ siRNA

Sigma-Aldrich announces the global release of MISSION® In VIVO QUALITY and iScale Oligos™ siRNA.

MISSION® In VIVO QUALITY and iScale Oligos™ siRNA are expected to allow researchers to successfully take the next step in their RNAi research with the highest purity and quality siRNA required for RNAi research in animal models.

These siRNA are believed by the company to be well suited to target validation and pre-clinical siRNA testing. Intermediate and large synthesis scales and a wide variety of modifications are also available.

"Increasingly, RNAi researchers are utilizing animal models to confirm findings from cell culture based assays or to explore the use of siRNA as a potential therapeutic agent," said Tim Fleming, Director of Global Commercial Marketing at Sigma-Aldrich.

"Our goal is to provide an siRNA that is capable of facilitating in vivo siRNA research, with the purity levels required for direct delivery or to be used as an essential part of an overall in vivo formulation strategy," Fleming added.

MISSION® In VIVO QUALITY siRNA are processed specifically for in vivo usage. This purification process includes RP-HPLC to ensure a high percentage of full-length product, dialysis on the annealed product to remove excess salts, 22 micrometer sterile filtration, and finally testing to ensure no endotoxins are present.

In addition, iScale Oligos™ synthesis scales can give customers the siRNA required for in vivo usage with amounts up to 100mg. MISSION® In VIVO QUALITY and iScale Oligos™ siRNA are available with many of the common modifications used to for tracking or stability, such as FAM, Cy5™, and Cy3™.